Modified Flavonoid Compound for Reducing Amyloid Proteins
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Alzheimer's disease are inadequate, as there is no cure and existing drugs only temporarily delay symptom progression, with a need for new compounds that can effectively reduce β-amyloid peptide formation and accumulation in the brain.
Innovation Solution
A modified flavonoid compound with an electrophilic group is used to enhance binding affinity to enzymes, specifically down-regulating β- and γ-secretase and up-regulating α-secretase, thereby reducing amyloid protein production, which is achieved by modifying naturally occurring flavonoids like myricetin with groups such as aldehyde, haloalkane, or fluorophenol.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If existing drugs (cholinesterase inhibitors or NMDA blockers) are used to treat Alzheimer's disease, then cognitive symptoms are temporarily delayed for 6-12 months, but there is no cure and symptoms eventually progress
Solution Approach 1:
The patent modifies the chemical structure of flavonoid compounds by introducing electrophilic groups (such as aldehyde, keto, or acyl groups) at specific positions (R5 or R6) to change the binding affinity parameters. This structural parameter change enables the compound to achieve irreversible or prolonged binding to secretase enzymes, transforming the temporary symptom delay into a more durable therapeutic effect that addresses the root cause of amyloid production.
Solution Approach 2:
The patent creates composite molecular structures by combining the core flavonoid scaffold with electrophilic functional groups. This composite approach integrates the biological activity of natural flavonoids with the high-affinity binding capability of electrophilic groups, resulting in a hybrid molecule that achieves both symptom management and disease modification.
2Reliability
If flavonoid compounds are modified with electrophilic groups to enhance binding affinity, then enzyme affinity and therapeutic effect are increased, but the chemical structure becomes more complex
Solution Approach 1:
The patent applies electrophilic groups at specific local positions (R5 or R6) of the flavonoid molecule rather than modifying the entire structure. This localized modification approach enhances binding affinity at the critical enzyme interaction site while maintaining the simplicity of the rest of the molecular structure, thus improving reliability without proportionally increasing overall complexity.
Solution Approach 2:
The patent systematically varies specific parameters (electrophilic group type and position) to optimize binding affinity. By changing discrete structural parameters rather than redesigning the entire molecule, the patent achieves high enzyme affinity while keeping the overall chemical structure relatively simple and manageable for synthesis.
3Object-generated harmful factors
If β- and γ-secretase are down-regulated and α-secretase is up-regulated, then amyloid protein production is reduced, but the mechanism is complex and requires precise enzymatic regulation
Solution Approach 1:
The patent extracts and targets the specific enzymatic activity responsible for amyloid production (β- and γ-secretase) rather than addressing the complex network of all secretase activities. By designing molecules that specifically inhibit the harmful enzymatic steps, the patent simplifies the therapeutic mechanism to focus on the root cause of amyloid accumulation.
Solution Approach 2:
The modified flavonoid compound acts as an intermediary molecule that mediates the regulation of secretase enzymes. The electrophilic groups in the compound facilitate binding to secretase enzymes, enabling the compound to serve as a therapeutic intermediary that coordinates the down-regulation of β- and γ-secretase and up-regulation of α-secretase in a controlled manner.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified flavonoid compounds effectively reduce β-amyloid production, slowing down neural degeneration and providing a potential therapeutic benefit for Alzheimer's disease and other neurological disorders by enhancing enzyme affinity and increasing the therapeutic effect.
Implementation Method 1
The binding enhancer is an electrophilic group that increases the enzyme affinity of the compound
Data Source
AI summary
The composition for treating neurological disorders such as Alzheimer's Disease is provided. The composition includes a modified flavonoid compound having enhanced binding affinity to metabolic modulating enzymes. The composition is effective to down-regulate beta- and gamma-secretase and up-regulate alpha secretase, which results in a reduction in amyloid proteins.